BlackRock Amends FibroGen Stake: Passive Investment Update
Ticker: KYNB · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in FibroGen, signaling a portfolio adjustment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership of FibroGen Inc. common stock as of December 31, 2023. This filing, Amendment No. 8, shows BlackRock's updated passive investment position in FibroGen, a pharmaceutical preparations company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence or strategy regarding FibroGen's future prospects.
Why It Matters
This filing updates BlackRock's passive ownership in FibroGen, providing transparency on a significant institutional investor's position, which can influence market perception.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in FibroGen, but this filing alone doesn't suggest a strong buy or sell signal. It's a routine update reflecting an institutional investor's portfolio management.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- FibroGen Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the date the SC 13G/A was filed
- Amendment No: 8 (number) — the specific amendment number for this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., as indicated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' and 'Names of reporting persons. BlackRock, Inc.'.
What is the subject company whose securities are being reported?
The subject company is FIBROGEN INC, as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: FIBROGEN INC' and 'FIBROGEN INC (Name of Issuer)'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under 'December 31, 2023 (Date of Event Which Requires Filing of this Statement)'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox selection.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding FIBROGEN INC (KYNB).